Page 146 - Read Online

Page 12 of 13 Alsulihem et al. Neuroimmunol Neuroinflammation 2019;6:13 I http://dx.doi.org/10.20517/2347-8659.2019.007

25. Hunter KF, Bharmal A, Moore KN. Long-term bladder drainage: Suprapubic catheter versus other methods: a scoping review.
Neurourol Urodyn 2013;32:944-51.
26. Esclarín De Ruz A, García Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with
spinal cord injury. J Urol 2000;164:1285-9.
27. Sugimura T, Arnold E, English S, Moore J. Chronic suprapubic catheterization in the management of patients with spinal cord injuries:
analysis of upper and lower urinary tract complications. BJU Int 2008;101:1396-400.
28. Caremel R, Feifer A, Corcos J. Management of neurogenic bladder with suprapubic cystostomy. In: Corcos J, Ginsburg D, Karsenty
G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton, FL, USA: CRC Press; 2015. p. 467-71.
29. Aharony S, Corcos J. Systemic and intrathecal pharmacologic treatment. In: Corcos J, Ginsburg D, Karsenty G, editors. Textbook of
the neurogenic bladder. 3rd ed. Boca Raton, FL, USA: CRC Press; 2015. p. 473-88.
30. Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability, and safety of oral
anti-muscarinics. Spinal Cord 2013;51:432-41.
31. Romo PGB, Smith CP, Cox A, Averbeck MA, Dowling C, et al. Non-surgical urologic management of neurogenic bladder after spinal
cord injury. World J Urol 2018;36:1555-68.
32. Munjuluri N, Wong W, Yoong W. Anticholinergic drugs for overactive bladder: a review of the literature and practical guide. Obstet
Gynecol 2007;9:9-14.
33. Schroder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin
hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled, multicentre trial. Neurourol
Urodyn 2016;35:582-8.
34. Krhut J, Borovička V, Bílková K, Sýkora R, Míka D, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor
overactivity - prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 2018;37:2226-33.
35. Soebadi MA, Hakim L, Van der Aa F, De Ridder D. Real-life data on mirabegron in neurogenic bladder dysfunction. Urol Int
2019;103:195-201.
36. Han SH, Cho IK, Jung JH, Jang SH, Lee BS. Long-term efficacy of mirabegron add-on therapy to antimuscarinic agents in patients
with spinal cord injury. Ann Rehabil Med 2019;43:54-61.
37. Smith CP. Intravesical pharmacologic treatment for neurogenic detrusor overactivity. In: Corcos J, Ginsburg D, Karsenty G, editors.
Textbook of the neurogenic bladder. 3rd ed. Boca Raton, FL, USA: CRC Press; 2015. p. 489-501.
38. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord
Med 2013;36:402-19.
39. Li GP, Wang XY, Zhang Y. Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity caused by
spinal cord injury: a systematic review and meta-analysis. Int Neurourol J 2018;22:275-86.
40. Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol
2016;5:63-71.
41. Peyronnet B, Gamé X, Vurture G, Nitti VW, Brucker BM. Botulinum toxin use in neurourology. Rev Urol 2018;20:84-93.
42. Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia 1994;32:795-805.
43. Krasmik D, Krebs J, van Ophoven A, Pannek J. Urodynamic results, clinical efficacy, and complication rates of sacral intradural
deafferentation and sacral anterior root stimulation in patients with neurogenic lower urinary tract dysfunction resulting from complete
spinal cord injury. Neurourol Urodyn 2014;33:1202-6.
44. Martens FM, den Hollander PP, Snoek GJ, Koldewijn EL, van Kerrebroeck PE, et al. Quality of life in complete spinal cord injury
patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn 2011;30:551-5.
45. Benard A, Verpillot E, Grandoulier AS, Perrouin-Verbe B, Chêne G, et al. Comparative cost-effectiveness analysis of sacral anterior
root stimulation for rehabilitation of bladder dysfunction in spinal cord injured patients. Neurosurgery 2013;73:600-8.
46. Herschorn S, Bailly GG. Urinary diversion. In: Corcos J, Ginsburg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed.
Boca Raton, FL, USA: CRC Press; 2015. p. 545-61.
47. Johnson EU, Singh G. Long-term outcomes of urinary tract reconstruction in patients with neurogenic urinary tract dysfunction.
Indian J Urol 2013;29:328-37.
48. Gurung PM, Attar KH, Abdul-Rahman A, Morris T, Hamid R, et al. Long-term outcomes of augmentation ileocystoplasty in patients
with spinal cord injury: a minimum of 10 years of follow-up. BJU Int 2012;109:1236-42.
49. Michel F, Ciceron C, Bernuz B, Boissier R, Gaillet S, et al. Botulinum toxin type A injection after failure of augmentation
enterocystoplasty performed for neurogenic detrusor overactivity: preliminary results of a salvage strategy. The ENTEROTOX study.
Urology 2019;129:43-7.
50. Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder.
Urology 1999;54:636-40.
51. Guillot-Tantay C, Chartier-Kastler E, Perrouin-Verbe MA, Denys P, Léon P, et al. Complications of non-continent cutaneous urinary
diversion in adults with spinal cord injury: a retrospective study. Spinal Cord 2018;56:856-62.
52. Schwartz SL, Kennelly MJ, McGuire EJ, Faerber GJ. Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary
tract dysfunction. J Urol 1994;152:99-102.
53. Atan A, Konety BR, Nangia A, Chancellor MB. Advantages and risks of ileovesicostomy for the management of neuropathic bladder.
Urology 1999;54:636-40.
54. Hellenthal NJ, Short SS, O’Connor RC, Eandi JA, Yap SA, et al. Incontinent ileovesicostomy: long-term outcomes and complications.
Neurourol Urodyn 2009;28:483-6.
55. Leng WW, Faerber G, Del Terzo M, McGuire EJ. Long-term outcome of incontinent ileovesicostomy management of severe lower